Golden Age Health

What Golden Age Health does

Golden Age Health (GAH) is a Singapore-incorporated pharmaceutical platform founded in 2023 that commercializes rare and specialty disease therapies in China and other underserved markets. The company operates as a B2B intermediary bridging East-West innovation—channeling global advanced therapies into China while simultaneously exporting high-potential Chinese biotech assets to global markets. GAH serves global pharmaceutical companies seeking China market entry and Chinese biotech firms pursuing global commercialization, targeting the roughly 400 million people affected by the approximately 7,000 identified rare diseases, of which only 5% have approved treatments.

GAH's product portfolio spans multiple modalities and indications, including Raxone (via its partnership with Chiesi Farmaceutici for China access), LX101 (Innostellar's gene therapy for inherited retinal dystrophies due to RPE65 mutation), and ZTALMY/ganaxolone, positioned as the first approved treatment in Mainland China for seizures associated with CDKL5 deficiency disorder. The platform is built on AI-powered patient finding and real-world data analytics to drive precise patient identification, omnichannel engagement, and value-based market access. GAH leverages China-specific regulatory pathways such as the Hainan Medical Pilot Zone and the Beijing Rare Disease Tianzhu Zone to compress time-to-patient, with end-to-end ownership spanning dossier preparation, regulatory strategy, market access, and supply-chain management.

Revenue is generated through flexible partnership structures with pharmaceutical and biotech counterparties, including up-front plus milestone payments, distribution and promotion arrangements, profit-share, and joint venture models (categorized under licensing/royalties revenue streams). The company is led by co-founders Michel Vounatsos (former CEO of Biogen), Yossi BenAmram (former President Europe/MEA/Russia at MSD and architect behind the Spinraza China launch), and Reda Rebib (former EQT Partners healthcare investor), supported by a core operational team of 11–50 employees concentrated in China, with affiliated regional partners extending the platform's reach into the Middle East, Africa, and Latin America.

Name

Golden Age Health

Legal name

Golden Age Health Pte. Ltd.

Website

https://gahbioventures.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Singapore-based pharmaceutical platform founded in 2023 that commercializes rare and specialty disease therapies in China and underserved markets, bridging global pharma innovations into China and Chinese biotech assets to global markets via flexible licensing and partnership models.

Ownership category

akta.pro rank

Product category

Rare Disease Pharmaceutical Commercialization

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Pharmaceutical Preparations (2834), Services-Health Services (8000)

akta.pro primary industry

Real-World Evidence (RWE) & HEOR for Development (HLAIALAI)

akta.pro secondary industry

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

Keywords

• Rare disease therapeutics
• Pharmaceutical commercialization
• Biotech market access
• Specialty disease therapies
• Pharmaceutical licensing partnerships

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Supply Chain, Technology or R&D, Others

Revenue model

1. Pharmaceutical partnership and licensing: Revenue generated through flexible partnership models including up-front + milestone payments, distribution & promotion arrangements, profit-share structures, and joint ventures with pharmaceutical companies commercializing rare and specialty disease treatments in China and Asia

Go-to-market motion2 records

Distribution channels1 record

Marketing channels2 records

Core offering

Golden Age Health is a pharmaceutical platform that commercializes rare and specialty disease therapies in China and Asia through flexible end-to-end partnership models covering regulatory strategy, market access, patient engagement, and real-world evidence generation. The company both supports global pharmaceutical companies expanding into China (e.g., Chiesi Farmaceutici for Raxone) and helps Chinese biotech companies (e.g., Innostellar for LX101 gene therapy) bridge their assets to global markets. Portfolio assets include Raxone, LX101, and ZTALMY (Ganaxolone), with execution powered by AI-driven patient finding and real-world data analytics.

Product overview

Golden Age Health is a pharmaceutical platform specializing in rare and specialty diseases, connecting the world's most advanced therapies with patients in China while sourcing high-potential assets from China's maturing biotech ecosystem for global development and commercialization. Their product portfolio includes Raxone (supporting Chiesi Farmaceutici for China market access), LX101 (Innostellar's gene therapy for inherited retinal dystrophies), and ZTALMY/Ganaxolone (the first approved treatment in Mainland China for CDKL5 deficiency disorder seizures). The company offers flexible partnership models covering the full commercialization spectrum from regulatory strategy to patient engagement.

Differentiator

Problem solved

Functional benefit

Products and services

• Raxone Raxone is a rare disease treatment being commercialized in China through GAH's partnership with Chiesi Farmaceutici, intended for patients with limited treatment access in the Chinese market.
• LX101 LX101 is a gene therapy targeting inherited retinal dystrophies caused by RPE65 gene mutation, developed by Innostellar and partnered with Golden Age Health for global development and commercialization.
• ZTALMY (Ganaxolone) ZTALMY (Ganaxolone) is the first approved treatment in Mainland China for seizures associated with CDKL5 deficiency disorder (CDD), commercialized through Golden Age Health's platform.

Quantifiable outcome

• Reduced time-to-patient by up to 40% in underserved regions
• +1 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Chiesi FarmaceuticicoreStrategic or Co-development PartnerGolden Age Health supports Chiesi Farmaceutici in expanding access to Raxone in China. Raxone is a product in GAH's portfolio focused on supporting Chiesi's rare disease treatment access in the Chinese market.
• InnostellarcoreStrategic or Co-development PartnerPartnership with Innostellar for gene therapy LX101 targeting inherited retinal dystrophies (IRD) due to RPE65 gene mutation. Innostellar is a Chinese biotech company with innovative assets that GAH is helping bridge to global markets.
• Belief BioMedminorStrategic or Co-development PartnerBelief BioMed is a partner in GAH's ecosystem for rare disease and specialty treatment commercialization.
• ImmunoforgeminorStrategic or Co-development PartnerImmunoforge is listed as a partner in GAH's product portfolio ecosystem.
• InternaminorStrategic or Co-development PartnerInterna (interna.bio) is a biotechnology partner in GAH's ecosystem.
• TenaciaminorStrategic or Co-development PartnerTenacia is listed as a partner company in GAH's ecosystem for rare disease solutions.
• ALZpathminorStrategic or Co-development PartnerALZpath is a biotechnology partner in GAH's ecosystem, appearing in the logos section alongside other biotech partners.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Clinigen Group: Specialty pharma services and access business providing early access, clinical trial supply, and commercialization support for rare-disease medicines. Closely comparable B2B model of bridging pharma partners with patients in underserved indications and geographies.
• Soleo Health: Specialty pharmacy and infusion services company that commercializes rare-disease and specialty therapies through partnership models with manufacturers — a directly comparable rare-disease commercialization intermediary.
• Inceptua: Provider of early access programs and pharma supply chain solutions for rare and specialty medicines across multiple regions. Comparable to GAH in offering end-to-end commercialization support with a focus on hard-to-access therapies.
• Tanner Pharma Group: Specialty access and commercialization firm focused on named-patient access, licensing, and distribution of rare-disease and specialty therapeutics — directly comparable to GAH's partner-licensing model for rare-disease drugs.

Broad incumbents

• EVERSANA: End-to-end commercialization services platform for specialty and rare-disease therapies, including market access, patient services, and real-world evidence — overlaps with GAH's full-stack commercialization model at larger scale.
• Piramal Pharma Solutions: Integrated pharma services and specialty commercialization business including CDMO capabilities and a global specialty drug distribution arm. Broadly comparable to GAH's commercialization-plus-supply-chain offering at greater scale.
• WuXi Biologics: China-based global CRDMO serving biologics developers with discovery, development, and commercial manufacturing. Broad incumbent serving the China biopharma ecosystem with capabilities that overlap GAH's biotech-Asia commercialization role.
• IQVIA: Global life sciences services leader combining real-world evidence, AI, clinical, and commercial services. Comparable to GAH's RWE/AI patient-finding capabilities while operating at vastly larger scale.

Regional players

• Tigermed: Leading China-headquartered clinical CRO offering drug development services across Asia with growing rare-disease exposure. Comparable on the China biotech-development side of GAH's two-way model.
• Vector Pharma: Specialty distribution and commercialization partner for rare-disease medicines across the Middle East and Africa. Comparable to GAH in bridging rare-disease manufacturers with underserved regional markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/golden-age-health

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Golden Age Health